The investment will specifically support the development of NG-350A through a Phase Ib clinical proof-of-concept study, FORTRESS which will assess the clinical complete response rates of the therapy
Under the agreement terms, EpimAb is set to receive an upfront payment, along with development and sales milestones that could exceed $1bn, provided multiple drug candidates reach commercialisation.
The designation is supported by the positive outcomes from the double-blind Phase III HERCULES trial, where the therapy showed a 31% delay in the time to onset of
This initiative is facilitated through a Named Patient Program (NPP), allowing patients to access these treatments based on clinical evidence and medical needs prior to regulatory approval. The
The total funding is set to amount to $9.1m and the initial research grant of $1m was announced in January this year. The additional funding from RSRT will
With this financing round, the company’s total funding reached more than $25m. Small molecule drugs developed by the company specifically target viral proteins crucial to the polyomavirus life
Acromegaly is a serious disease which is generally caused by a benign pituitary adenoma. Paltusotine would be the first, once-daily, oral selective somatostatin receptor type 2 nonpeptide agonist
TO-208, known as VP-102 in the US and marketed under the brand name YCANTH, contains cantharidin as its active ingredient. A Phase III clinical trial was conducted in
This designation marks the beginning of the UK Innovative Licensing and Access Pathway (ILAP), which is designed to expedite the development and access of new medicines in the
This move grants Theratechnologies the ‘rights’ to potentially introduce treatments for familial chylomicronaemia syndrome (FCS), hereditary angioedema (HAE), and severe hypertriglyceridemia (sHTG) within the Canadian market. Under the
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.